Moberg Pharma to receive Eurostars grant of EUR 0.9 million
STOCKHOLM, June 24, 2015. Moberg Pharma AB (OMX: MOB) today announced that a grant of EUR 0.9 million in public funding has been approved by Eurostars for a project proposal related to late-stage development of Moberg Pharma’s BUPI project.The Eurostars project “BUPI - a long-acting lozenge with bupivacaine for pain relief of Oral Mucositis in cancer patients” will be managed by Moberg Pharma and includes six external partners in Sweden and Denmark: Oracain ApS, TFS Trial Form Support ApS, Aarhus University Hospital, University Hospital Herlev, PCG Clinical Services AB and Skåne University